These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24293567)

  • 21. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
    Halfon P; Bourliere M; Ouzan D; Maor Y; Renou C; Wartelle C; Pénaranda G; Tran A; Botta D; Oules V; Castellani P; Portal I; Argiro L; Dessein A
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):931-5. PubMed ID: 21900787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin.
    Ramos JA; Ramos AL; Hoffmann L; Perez Rde M; Coelho HS; Urményi TP; Silva R; Rondinelli E; Villela-Nogueira CA
    Mem Inst Oswaldo Cruz; 2012 Nov; 107(7):888-92. PubMed ID: 23147144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
    Sarrazin C; Susser S; Doehring A; Lange CM; Müller T; Schlecker C; Herrmann E; Lötsch J; Berg T
    J Hepatol; 2011 Mar; 54(3):415-21. PubMed ID: 21112657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
    Riva E; Scagnolari C; Monteleone K; Selvaggi C; Picardi A; Mazzarelli C; Pizzigallo E; Vincenzi B; Carducci A; Antonaci S; Giannelli G; Antonelli G
    J Viral Hepat; 2012 Sep; 19(9):650-3. PubMed ID: 22863269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
    Bizid S; Bouali R; Ouedrani A; Mrabet A; Ben Abdallah H; Ghazouani E; Abdelli N
    Tunis Med; 2016 Jan; 94(1):6-11. PubMed ID: 27525598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy.
    López-Rodríguez R; Hernández-Bartolomé Á; Borque MJ; Rodríguez-Muñoz Y; Martín-Vílchez S; Trapero-Marugán M; García-Buey L; Muñoz de Rueda P; Rodrigo L; Vidal-Castiñeira JR; Salmerón J; Moreno-Otero R; Sanz-Cameno P
    Genes Immun; 2013; 14(5):317-24. PubMed ID: 23615070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
    Kamal SM; Kassim SK; Ahmed AI; Mahmoud S; Bahnasy KA; Hafez TA; Aziz IA; Fathelbab IF; Mansour HM
    Am J Gastroenterol; 2014 Feb; 109(2):199-211. PubMed ID: 24445571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of Interleukin 28B rs12979860 and rs8099917 Polymorphisms and T-helper 1 Response in Hepatitis C Virus Patients.
    Ea R; Aa G; Ag ES; Ma A
    Egypt J Immunol; 2015 Jun; 22(2):57-68. PubMed ID: 28502145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
    Ladero JM; Martin EG; Fernández C; Carballo M; Devesa MJ; Martínez C; Suárez A; Díaz-Rubio M; Agúndez JA
    J Gastroenterol Hepatol; 2012 Feb; 27(2):279-85. PubMed ID: 21722179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.
    Falleti E; Bitetto D; Fabris C; Fattovich G; Cussigh A; Cmet S; Ceriani E; Fornasiere E; Pasino M; Ieluzzi D; Pirisi M; Toniutto P
    Hepatology; 2012 Nov; 56(5):1641-50. PubMed ID: 22610885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study.
    Shaker O; Rashad A; Abd El Aziz G; El Raziky M
    Cell Biochem Biophys; 2015 Jan; 71(1):307-14. PubMed ID: 25115611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
    Gupta AC; Trehanpati N; Sukriti S; Hissar S; Midha V; Sood A; Sarin SK
    J Med Virol; 2014 Apr; 86(4):707-12. PubMed ID: 24415442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.